Vectr Systems, Inc. (VECT) IPO Prices at $17

VectivBio Holding AG, (Nasdaq: VECT), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need, today announced the pricing of its initial public offering of 7,500,000 ordinary shares at a public offering price of $17.00 per share. The gross proceeds to Vectiv, before deducting underwriting discounts and commissions and offering expenses, are expected to be $127.5 million. All of the ordinary shares are being offered by Vectiv. In addition, Vectiv has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 ordinary shares at the initial public offering price, less the underwriting discounts and commissions.

Vectiv’s shares are expected to begin trading on the Nasdaq Global Select Market on Friday, April 9, 2021 under the ticker symbol “VECT.” The offering is expected to close on April 13, 2021, subject to customary closing conditions.

BofA Securities, SVB Leerink and Credit Suisse are acting as joint book-running managers for the offering. LifeSci Capital is also acting as an underwriter for the offering.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• After record IPO, Musk's SpaceX faces next test in market debut
• SpaceX prices historic IPO at $135/share in largest ever new listing